Samuel A Wells
Affiliation: National Institutes of Health
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an updateSamuel A Wells
Jr, MD, Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814
J Clin Endocrinol Metab 98:3149-64. 2013..Information gained from molecular testing, biochemical analysis, and clinical evaluation is important in providing effective management of patients with either early or advanced-stage MTC. ..
- Targeting the RET pathway in thyroid cancerSamuel A Wells
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:7119-23. 2009..Also, recently developed molecular therapeutics that target the RET pathway have shown activity in clinical trials of patients with advanced MTC, a disease for which there has been no effective therapy...
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialSamuel A Wells
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 30:134-41. 2012....
- Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastasesAnna Tamburrino
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 18:3532-40. 2012..Understanding the molecular pathogenesis of medullary thyroid carcinoma (MTC) is prerequisite to the design of targeted therapies for patients with advanced disease...